Public Sector Pension Investment Board Buys Shares of 381,172 Sarepta Therapeutics, Inc. $SRPT

Public Sector Pension Investment Board bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 381,172 shares of the biotechnology company’s stock, valued at approximately $7,345,000.

Several other institutional investors have also recently made changes to their positions in SRPT. Byrne Asset Management LLC purchased a new stake in Sarepta Therapeutics in the third quarter worth about $33,000. Atlantic Union Bankshares Corp bought a new stake in shares of Sarepta Therapeutics in the 3rd quarter valued at about $48,000. AlphaQuest LLC lifted its position in shares of Sarepta Therapeutics by 118.3% in the 3rd quarter. AlphaQuest LLC now owns 2,561 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,388 shares during the period. Covestor Ltd lifted its position in shares of Sarepta Therapeutics by 1,081.8% in the 3rd quarter. Covestor Ltd now owns 2,789 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 2,553 shares during the period. Finally, GAMMA Investing LLC boosted its stake in shares of Sarepta Therapeutics by 285.6% during the third quarter. GAMMA Investing LLC now owns 3,089 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 2,288 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Buying and Selling

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total transaction of $294,201.97. Following the transaction, the chief operating officer owned 193,300 shares in the company, valued at approximately $4,312,523. This represents a 6.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.60% of the stock is owned by company insiders.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $17.88 on Wednesday. Sarepta Therapeutics, Inc. has a fifty-two week low of $10.41 and a fifty-two week high of $110.00. The company has a market cap of $1.87 billion, a PE ratio of -5.94, a P/E/G ratio of 0.45 and a beta of 0.39. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 2.95. The business has a 50-day simple moving average of $20.94 and a two-hundred day simple moving average of $20.20.

Analysts Set New Price Targets

A number of analysts have weighed in on SRPT shares. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a report on Tuesday, January 27th. Robert W. Baird reduced their price target on Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a research report on Tuesday, November 4th. Wells Fargo & Company dropped their price objective on Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Royal Bank Of Canada boosted their target price on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a report on Thursday, January 8th. Finally, Wedbush increased their price target on shares of Sarepta Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Nine investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $33.84.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.